Daijiworld Media Network - Hyderabad

Hyderabad, Dec 27: Indian Immunologicals Limited (IIL), one of the country’s leading vaccine manufacturers, has refuted claims by Australian health authorities regarding the circulation of fake doses of its anti-rabies vaccine Abhayrab in India.

In an official statement, IIL issued a clarification in response to an alert issued by the Australian Technical Advisory Group, which had warned about the alleged circulation of counterfeit batches of the vaccine since November 2023.

The company asserted that the alert does not reflect the current ground reality in India. Reassuring healthcare professionals and the general public, IIL stated that every batch of vaccine manufactured in the country undergoes mandatory testing and is released only after approval by the Central Drugs Laboratory.

IIL emphasised that vaccines are made available for sale or administration strictly in accordance with regulatory protocols, ensuring safety, quality and efficacy.

The vaccine manufacturer urged stakeholders not to panic and reiterated its commitment to maintaining the highest standards of manufacturing and quality control, while working closely with regulatory authorities to address any concerns.